Goldman Sachs Starts Biohaven Pharmaceutical Holding (BHVN) at Buy

Goldman Sachs analyst Paul Choi initiates coverage on Biohaven Pharmaceutical Holding (NYSE: BHVN) with a Buy rating and a price target of $92.00.

• Believes rimegepant's profile (Phase 3, faster onset, less rescue meds, clean safety, lower price) can drive sales beyond consensus expectations even on conservative numbers.
• Believes consensus attributes limited contribution from the piopeline which Choi sees as an attractive upside opportunity.

For an analyst ratings summary and ratings history on Biohaven Pharmaceutical Holding click here. For more ratings news on Biohaven Pharmaceutical Holding click here.

Shares of Biohaven Pharmaceutical Holding closed at $57.06 yesterday.

You May Also Be Interested In

• Biohaven Pharma (BHVN) PT Raised to $23 at RBC Capital
• JPMorgan Assumes salesforce.com (CRM) at Overweight, 'Overblown Concerns'
• Freedom Broker Upgrades Serve Robotics (SERV) to Buy